Breaking Finance News

Northland Capital reiterated ValiRx PLC (LON:VAL) to Corporate in a report released earlier today.

Boasting a price of 6.63GBX, ValiRx PLC (LON:VAL) traded 9.39% higher on the day. With the last close down -16.09% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. ValiRx PLC has recorded a 50-day average of 7.01GBX and a two hundred day average of 7.99GBX. Volume of trade was down over the average, with 491,446 shares of VAL changing hands under the typical 1,445,340

Northland Capital has reiterated ValiRx PLC (LON:VAL) to Corporate in a report released on Tuesday November 29, 2016.

Recent Performance Chart

ValiRx PLC (LON:VAL)

ValiRx PLC has with a one year low of 5.75GBX and a one year high of 25.24GBX and has a market capitalization of 0 GBX.

A total of 1 analyst has released a report on ValiRx PLC. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of 1.05GBX.

Brief Synopsis About ValiRx PLC (LON:VAL)

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *